From physiology to pharmacy: Developments in the pathogenesis and treatment of recurrent urinary tract infections

Current Urology Reports

Volumn 14, Issue 5, 2013, Pages 448-456

  Silverman, Jennifer A ^a   Schreiber, Henry L ^a   Hooton, Thomas M ^b   Hultgren, Scott J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic resistance; FimH; Mannoside; Pilicide; Recurrent urinary tract infection; Stress response

Indexed keywords

ADHESIN; CIPROFLOXACIN; COTRIMOXAZOLE; CRANBERRY EXTRACT; IBUPROFEN; MANNOSIDE; NITROFURANTOIN; VIRULENCE FACTOR;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BACTERIUM CARRIER; BACTERIUM PILUS; CRANBERRY JUICE; CYSTITIS; FEMALE; HUMAN; NONHUMAN; PATHOGENESIS; POSTMENOPAUSE; RECURRENCE RISK; RECURRENT INFECTION; RECURRENT URINARY TRACT INFECTION; REINFECTION; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; HUMANS; RECURRENCE; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; URODYNAMICS;

EID: 84886772177     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0354-5     Document Type: Article

References (103)

1. Foxman B, Barlow R, D'Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10:509-15.
2. Griebling TL: Urinary Tract Infection in Women. In: Litwin MS, Saigal CS, editors. Urologic diseases in America. US DHHS, PHS, NIH, NIDDKD. Washington DC: US GPO; 2007. 587-620.
3. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7:653-60.
4. Hung CS, Dodson KW, Hultgren SJ. A murine model of urinary tract infection. Nat Protoc. 2009;4:1230-43.
5. Hannan TJ, Totsika M, Mansfield KJ, et al. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616-48.
6. Thumbikat P, Berry RE, Schaeffer AJ, Klumpp DJ. Differentiation-induced uroplakin III expression promotes urothelial cell death in response to uropathogenic E. coli. Microbes Infect. 2009;11:57-65.
7. Thumbikat P, Berry RE, Zhou G, et al. Bacteria-induced uroplakin signaling mediates bladder response to infection. PLoS Pathog. 2009;5:e1000415.
8. Song J, Bishop BL, Li G, et al. TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder. Cell Host Microbe. 2007;1:287-98.
9. Anderson GG, Palermo JJ, Schilling JD, et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301:105-7.
10. Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA. 2006;103:14170-5.
11. • Hannan TJ, Mysorekar IU, Hung CS, et al. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog. 2010;6:e1001042. This important work identified a connection between inflammation and UTI outcome in mice. More severe inflammatory responses correlated with a predisposition for chronic UTI, suggesting the immune response to an initial UTI affects the likelihood of experiencing future UTIs.
12. Schwartz DJ, Chen SL, Hultgren SJ, Seed PC. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infect Immun. 2011;79:4250-9.
13. Walters MS, Lane MC, Vigil PD, et al. Kinetics of uropathogenic Escherichia coli metapopulation movement during urinary tract infection. MBio. 2012; 3.
14. Hunstad DA, Justice SS. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu Rev Microbiol. 2010;64:203-21.
15. Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol. 2010;7:430-41.
16. • Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103-20. This reference discusses the emerging worldwide problem of antimicrobial resistance and current empiric treatment strategies for uncomplicated cystitis and pyelonephritis.
17. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2005;26:380-8.
18. Schito GC, Naber KG, Botto H, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34:407-13.
19. Bonkat G, Muller G, Braissant O, et al. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates. World J Urol. 2013.
20. Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151:1194-205.
21. Ikaheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996;22:91-9.
22. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. New Engl J Med. 2012;366:1028-37.
23. Yamamoto S, Tsukamoto T, Terai A, et al. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. J Urol. 1997;157:1127-9.
24. Czaja CA, Stamm WE, Stapleton AE, et al. Prospective cohort study of microbial and inflammatory events immediately preceding Escherichia coli recurrent urinary tract Infection in women. J Infect Dis. 2009;200:528-36.
25. Ejrnaes K, Sandvang D, Lundgren B, et al. Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women. J Clin Microbiol. 2006;44:1776-81.
26. Foxman B, Zhang L, Tallman P, et al. Virulence characteristics of Escherichia coli causing first urinary tract infection predict risk of second infection. J Infect Dis. 1995;172:1536-41.
27. Kärkkäinen U, Ikaheimo R, Katila M-L, Siitonen A. Recurrence of urinary tract infections in adult patients with community-acquired pyelonephritis caused by E. coli: a 1-year follow-up. Scand J Infect Dis. 2000;32:495-9.
28. Kõljalg S, Truusalu K, Vainumäe I, et al. Persistence of Escherichia coli clones and phenotypic and genotypic antibiotic resistance in recurrent urinary tract infections in childhood. J Clin Microbiol. 2009;47:99-105.
29. Kunin CM. A ten-year study of bacteriuria in schoolgirls: final report of bacteriologic, urologic, and epidemiologic findings. J Infect Dis. 1970;122:382-93.
30. Luo Y, Ma Y, Zhao Q, et al. Similarity and divergence of phylogenies, antimicrobial susceptibilities, and virulence factor profiles of Escherichia coli isolates causing recurrent urinary tract infections that persist or result from reinfection. J Clin Microbiol. 2012;50:4002-7.
31. McGeachie J. Recurrent infection of the urinary tract: reinfection or recrudescence? Brit Med J. 1966;1:952-4.
32. Pryles CV, Glagovsky A. Serological characterization of Escherichia coli. study in acute and recurrent urinary tract infections in infants and children. Pediatrics. 1965;36:219-24.
33. Russo TA, Stapleton A, Wenderoth S, et al. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J Infect Dis. 1995;172:440-5.
34. Skjøt-Rasmussen L, Hammerum AM, Jakobsen L, et al. Persisting clones of Escherichia coli isolates from recurrent urinary tract infection in men and women. J Med Microbiol. 2011;60:550-4.
35. Winberg J, Andersen HJ, Bergström T, et al. Epidemiology of symptomatic urinary tract infection in childhood. Acta Paediatr. 1974;63:1-20.
36. • Wang C, Symington JW, Ma E, et al. Estrogenic modulation of uropathogenic Escherichia coli infection pathogenesis in a murine menopause model. Infect Immun. 2013;81:733-9. This paper establishes an ovariectomized mouse model to mimic menopause, finding that more QIRs are present in ovariectomized mice and observing a protective effect of estrogen therapy.
37. Foxman B. Urinary tract infection in postmenopausal women. Curr Infect Dis Rep. 1999;1:367-70.
38. •• Chen SL, Wu M, Henderson JP, et al. Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. Sci Transl Med. 2013;5:184ra160. This work describes a seminal finding: E. coli isolates found in the urinary tract are not necessarily less fit than those found in the intestine, and UTI recurrences could be due to the introduction of more fit strains of E. coli than the ones that caused previous episodes. This paper calls attention to the need to investigate the gut as a reservoir for UPEC.
39. Nowrouzian F, Hesselmar B, Saalman R, et al. Escherichia coli in infants' intestinal microflora: colonization rate, strain turnover, and virulence gene carriage. Pediatr Res. 2003;54:8-14.
40. Beerepoot MA, ter Riet G, Nys S, et al. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med. 2011;171:1270-8.
41. Cunha BA. Prophylaxis for recurrent urinary tract infections: nitrofurantoin, not trimethoprim-sulfamethoxazole or cranberry juice. Arch Intern Med. 2012;172:82. author reply 82-83.
42. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother. 1994;33(Suppl A):23-30.
43. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;2012(60):616-31.
44. Blango MG, Mulvey MA. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother. 2010;54:1855-63.
45. Chen CS, Ho DR, Chang PJ, et al. Urine post equivalent daily cranberry juice consumption may opsonize uropathogenicity of Escherichia coli. J Infect Chemother. 2013.
46. Sobota AE. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. J Urol. 1984;131:1013-6.
47. Gupta K, Chou MY, Howell A, et al. Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. J Urol. 2007;177:2357-60.
48. Barbosa-Cesnik C, Brown MB, Buxton M, et al. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis. 2011;52:23-30.
49. Takahashi S, Hamasuna R, Yasuda M, et al. A randomized clinical trial to evaluate the preventive effect of cranberry juice (UR65) for patients with recurrent urinary tract infection. J Infect Chemother. 2013;19:112-7.
50. Wang CH, Fang CC, Chen NC, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:988-96.
51. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10, CD001321.
52. • Bleidorn J, Gagyor I, Kochen MM, et al. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? - results of a randomized controlled pilot trial. BMC Med. 2010;8:30. This is a small pilot trial that raises the intriguing possibility that anti-inflammatories may have a role in the treatment of acute cystitis.
53. Schwartz DJ, Hultgren SJ. Uropathogenic Escherichia coli Virulence and Gene Regulation. In: Darwin AJ, Vasil ML, editors. Regulation of bacterial virulence. Washington, DC: ASM Press; 2012. p. 135-55.
54. Spurbeck RR, Stapleton AE, Johnson JR, et al. Fimbrial profiles predict virulence of uropathogenic Escherichia coli strains: contribution of ygi and yad fimbriae. Infect Immun. 2011;79:4753-63.
55. Hung CS, Bouckaert J, Hung D, et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol. 2002;44:903-15.
56. Mulvey MA, Lopez-Boado YS, Wilson CL, et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science. 1998;282:1494-7.
57. Wu XR, Sun TT, Medina JJ. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci USA. 1996;93:9630-5.
58. Bouckaert J, Berglund J, Schembri M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol. 2005;55:441-55.
59. Han Z, Pinkner JS, Ford B, et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem. 2010;53:4779-92.
60. Han Z, Pinkner JS, Ford B, et al. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem. 2012;55:3945-59.
61. •• Cusumano CK, Pinkner JS, Han Z, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med. 2011;3:109ra115. This work describes optimization and murine bioavailability studies of small anti-adhesion molecules. Importantly, these molecules could treat and prevent UTI, and had a synergistic effect when combined with TMP/SMX treatment.
62. Schwardt O, Rabbani S, Hartmann M, et al. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Bioorg Med Chem. 2011;19:6454-73.
63. Jiang X, Abgottspon D, Kleeb S, et al. Antiadhesion therapy for urinary tract infections-a balanced PK/PD profile proved to be key for success. J Med Chem. 2012;55:4700-13.
64. Scharenberg M, Schwardt O, Rabbani S, Ernst B. Target selectivity of FimH antagonists. J Med Chem. 2012;55:9810-6.
65. Pinkner JS, Remaut H, Buelens F, et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA. 2006;103:17897-902.
66. Chorell E, Pinkner JS, Bengtsson C, et al. Design and synthesis of fluorescent pilicides and curlicides: bioactive tools to study bacterial virulence mechanisms. Chemistry. 2012;18:4522-32.
67. Aberg V, Fallman E, Axner O, et al. Pilicides regulate pili expression in E. coli without affecting the functional properties of the pilus rod. Mol Biosyst. 2007;3:214-8.
68. Cegelski L, Pinkner JS, Hammer ND, et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol. 2009;5:913-9.
69. • Brumbaugh AR, Mobley HL. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines. 2012;11:663-76. This work is an excellent, comprehensive review of advancements made in UTI vaccines.
70. Alteri CJ, Hagan EC, Sivick KE, et al. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog. 2009;5:e1000586.
71. Wieser A, Romann E, Magistro G, et al. A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun. 2010;78:3432-42.
72. Langermann S, Palaszynski S, Barnhart M, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997;276:607-11.
73. Poggio TV, La Torre JL, Scodeller EA. Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge. Can J Microbiol. 2006;52:1093-102.
74. Langermann S, Mollby R, Burlein JE, et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis. 2000;181:774-8.
75. Karam MR, Oloomi M, Mahdavi M, et al. Assessment of immune responses of the flagellin (FliC) fused to FimH adhesin of uropathogenic Escherichia coli. Mol Immunol. 2013;54:32-9.
76. Nesta B, Spraggon G, Alteri C, et al.: FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 2012, 3.
77. Roberts JA, Kaack MB, Baskin G, et al. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J Urol. 2004;171:1682-5.
78. Alteri CJ, Smith SN, Mobley HL. Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle. PLoS Pathog. 2009;5:e1000448.
79. Donovan GT, Norton JP, Bower JM, Mulvey MA. Adenylate cyclase and the cyclic AMP receptor protein modulate stress resistance and virulence capacity of uropathogenic Escherichia coli. Infect Immun. 2013;81:249-58.
80. Torres AG, Redford P, Welch RA, Payne SM. TonB-dependent systems of uropathogenic Escherichia coli: aerobactin and heme transport and TonB are required for virulence in the mouse. Infect Immun. 2001;69:6179-85.
81. Henderson JP, Crowley JR, Pinkner JS, et al. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathog. 2009;5:e1000305.
82. Garcia EC, Brumbaugh AR, Mobley HL. Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection. Infect Immun. 2011;79:1225-35.
83. Russo TA, McFadden CD, Carlino-MacDonald UB, et al. The siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect Immun. 2003;71:7164-9.
84. Durant L, Metais A, Soulama-Mouze C, et al. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect Immun. 2007;75:1916-25.
85. Chaturvedi KS, Hung CS, Crowley JR, et al. The siderophore yersiniabactin binds copper to protect pathogens during infection. Nat Chem Biol. 2012;8:731-6.
86. Stock AM, Robinson VL, Goudreau PN. Two-component signal transduction. Annu Rev Biochem. 2000;69:183-215.
87. Kostakioti M, Hadjifrangiskou M, Pinkner JS, Hultgren SJ. QseC-mediated dephosphorylation of QseB is required for expression of genes associated with virulence in uropathogenic Escherichia coli. Mol Microbiol. 2009;73:1020-31.
88. Kostakioti M, Hadjifrangiskou M, Cusumano CK, et al. Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection. Infect Immun. 2012;80:2826-34.
89. • Hadjifrangiskou M, Kostakioti M, Chen SL, et al. A central metabolic circuit controlled by QseC in pathogenic Escherichia coli. Mol Microbiol. 2011;80:1516-29. This paper links both virulence and metabolism of UPEC with one two-component system and suggests the potential for using this system as a new target for antimicrobials.
90. Debnath I, Norton JP, Barber AE, et al. The Cpx stress response system potentiates the fitness and virulence of uropathogenic Escherichia coli. Infect Immun. 2013;81:1450-9.
91. Hung DL, Raivio TL, Jones CH, et al. Cpx signaling pathway monitors biogenesis and affects assembly and expression of P pili. EMBO J. 2001;20:1508-18.
92. Hernday AD, Braaten BA, Broitman-Maduro G, et al. Regulation of the pap epigenetic switch by CpxAR: phosphorylated CpxR inhibits transition to the phase ON state by competition with Lrp. Mol Cell. 2004;16:537-47.
93. Winberg J, Mollby R, Bergstrom J, et al. The PapG-adhesin at the tip of P-fimbriae provides Escherichia coli with a competitive edge in experimental bladder infections of cynomolgus monkeys. J Exp Med. 1995;182:1695-702.
94. Lane MC, Mobley HL. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int. 2007;72:19-25.
95. Schwan WR, Lee JL, Lenard FA, et al. Osmolarity and pH growth conditions regulate fim gene transcription and type 1 pilus expression in uropathogenic Escherichia coli. Infect Immun. 2002;70:1391-402.
96. Rentschler AE, Lovrich SD, Fitton R, et al. OmpR regulation of the uropathogenic Escherichia coli fimB gene in an acidic/high osmolality environment. Microbiology. 2013;159:316-27.
97. Storz G, Imlay JA. Oxidative stress. Curr Opin Microbiol. 1999;2:188-94.
98. Hryckowian AJ, Welch RA. RpoS contributes to phagocyte oxidase-mediated stress resistance during urinary tract infection by Escherichia coli CFT073. MBio. 2013;4:e00023-00013.
99. Lundberg JO, Ehren I, Jansson O, et al. Elevated nitric oxide in the urinary bladder in infectious and noninfectious cystitis. Urology. 1996;48:700-2.
100. Poljakovic M, Svensson ML, Svanborg C, et al. Escherichia coli-induced inducible nitric oxide synthase and cyclooxygenase expression in the mouse bladder and kidney. Kidney Int. 2001;59:893-904.
101. Bower JM, Mulvey MA. Polyamine-mediated resistance of uropathogenic Escherichia coli to nitrosative stress. J Bacteriol. 2006;188:928-33.
102. Lewis K. Persister cells. Annu Rev Microbiol. 2010;64:357-72.
103. • Norton JP, Mulvey MA. Toxin-antitoxin systems are important for niche-specific colonization and stress resistance of uropathogenic Escherichia coli. PLoS Pathog. 2012;8:e1002954. This work identifies several toxin-antitoxin pairs as being important for stress resistance and bladder and kidney persistence in UPEC.